The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia
Marius Külp, Anna Lena Siemund, Patrizia Larghero, Alissa Dietz, Julia Alten, Gunnar Cario, Cornelia Eckert, Aurélie Caye‐Eude, Hélène Cavé, Michela Bardini, Giovanni Cazzaniga, Paola De Lorenzo, Maria Grazia Valsecchi, Laura Diehl, Halvard Bonig, Claus Meyer, Rolf Marschalek
Abstract
. This was impaired through treatment with a neutralizing ICOSLG antibody. These findings imply ICOSLG (1) as a relapse-predicting biomarker, and (2) as a therapeutic target involved in a potential immune evasion relapse-mechanism of infant t(4;11) ALL.
Topics & Concepts
BiomarkerOncologyMedicineImmune systemImmunotherapyCohortChromosomal translocationImmunologyInternal medicineCancer researchBiologyGeneGeneticsAcute Lymphoblastic Leukemia researchLung Cancer Research StudiesImmune Cell Function and Interaction